Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04114539
Other study ID # EBS-101-OL-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 4, 2019
Est. completion date November 11, 2022

Study information

Verified date November 2023
Source Emalex Biosciences Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.


Description:

This was an international, multicenter, open-label, long term extension study to evaluate the safety of ecopipam tablets for the treatment of pediatric subjects (aged ≥6 to ≤18 years at Baseline) with Tourette Syndrome. Participants who completed the Phase 2b, randomized, double-blind, efficacy and safety study (EBS-101-CL-001) without major reportable protocol deviations, and who met all the inclusion/exclusion criteria for this study were eligible to participate in this study. All participants were titrated to a target dose of 2 mg/kg/day as participants rolled over from the Phase 2b double-blind efficacy and safety study were tapered off study drug to maintain the blind from that study. Participants were to complete study visits every month for 1 year. Follow-up visits were conducted 7 and 14 days after the last dose of the study drug and a follow-up phone call was conducted 30 days after the last dose of study drug


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date November 11, 2022
Est. primary completion date November 11, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: - Subjects must have completed the EBS-101-CL-001 study through the Day 14 Follow Up Visit within the last 30 days (or longer with permission of the medical monitor) without a major reportable protocol deviation and must be someone the Investigator feels would benefit from continued participation. Exclusion Criteria: - Certain mood or psychiatric disorders (i.e., dementia, bipolar disorder, schizophrenia, major depressive disorder). - Unstable medical illness or clinically significant lab abnormalities. - Risk of suicide. - Pregnant or lactating women. - Moderate to severe renal insufficiency. - Positive urine drug screen. - Certain medications that would lead to drug interactions.

Study Design


Intervention

Drug:
Ecopipam
Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.

Locations

Country Name City State
Canada The Kids Clinic Inc Ajax Ontario
Canada CHU Sainte-Justine Montreal Quebec
Canada Center for Pediatric Excellence Ottawa Ontario
France CHU Poitiers Poitiers
Germany Pharmakologisches Studienzentrum Chemnitz GmbH Mittweida
Poland Centrum Bada Klinicznych PI-House Sp. z o.o. Gdansk
Poland Gdanskie Centrum Zdrowia Sp z o.o. Gdansk
Poland Uniwersyteckie Centrum Kliniczne Gdansk
Poland NZOZ Wielospecjalistyczna Poradnia Lekarska Synapsis Katowice
Poland Centrum Medyczne Plejady Krakow
Poland Wojewdzki Specjalistyczny Szpital Dziecicy im. sw. Ludwika w Krakowie Krakow
Poland Med-Polonia Sp. z o. o. Poznan
United States Advanced Research Center Inc. Anaheim California
United States Michigan Clinical Research Institute PC Ann Arbor Michigan
United States Rare Disease Research, LLC Atlanta Georgia
United States Quest Therapeutics of Avon Lake Avon Lake Ohio
United States Houston Clinical Trials LLC Bellaire Texas
United States Neurobehavioral Medicine Group Bloomfield Hills Michigan
United States Massachusetts General Hospital Boston Massachusetts
United States Coastal Pediatric Research Charleston South Carolina
United States University of Virginia Charlottesville Virginia
United States Rush University Medical Center Chicago Illinois
United States The University of Chicago Hospitals Chicago Illinois
United States Cincinnati Childrens Hospital Medical Center Cincinnati Ohio
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Relaro Medical Trials Dallas Texas
United States Harmonex Neuroscience Research Dothan Alabama
United States Eastside Therapeutic Resource Inc dba Core Clinical Research Everett Washington
United States North Texas Clinical Trials Fort Worth Texas
United States Sarkis Clinical Trials Gainesville Florida
United States Northwest Florida Clinical Research Group, LLC Gulf Breeze Florida
United States Research in Miami Inc. Hialeah Florida
United States Baylor College of Medicine Houston Texas
United States Center for Psychiatry and Behavioral Medicine Inc. Las Vegas Nevada
United States Alivation Research, LLC Lincoln Nebraska
United States UCLA Los Angeles California
United States Suburban Research Associates Media Pennsylvania
United States University of Miami Miami Florida
United States North Star Medical Research LLC Middleburg Heights Ohio
United States The NeuroCognitive Institute Mount Arlington New Jersey
United States AMR - Baber Research Inc. Naperville Illinois
United States Access Clinical Trials, Inc. Nashville Tennessee
United States Vanderbilt University Medical Center Nashville Tennessee
United States Yale School of Medicine New Haven Connecticut
United States Hapworth Research Inc. New York New York
United States Mood Disorders Consulting Medicine PLLC New York New York
United States Mount Sinai School of Medicine New York New York
United States New York Neurology Associates P.C New York New York
United States MedBio Trials North Miami Florida
United States APG Research LLC Orlando Florida
United States Psychiatric Associates Overland Park Kansas
United States Phoenix Children's Hospital Phoenix Arizona
United States Finger Lakes Clinical Research Rochester New York
United States St. Charles Psychiatric Associates dba Midwest Research Group Saint Charles Missouri
United States Movement Disorders Center Saint Louis Missouri
United States University of South Florida Saint Petersburg Florida
United States Road Runner Research Ltd. San Antonio Texas
United States PCSD-Feighner Research San Diego California
United States Syrentis Clinical Research Santa Ana California
United States Meridian Clinical Research Savannah Georgia
United States Noetic Psychiatry Springville Utah
United States Pediatric Epilepsy and Neurology Specialists Tampa Florida
United States Clinical Research Center of NJ Voorhees New Jersey
United States Pediatric Neurology, PA Winter Park Florida
United States Helen DeVos Children's Hospital / Spectrum Health Medical Group Wyoming Michigan

Sponsors (1)

Lead Sponsor Collaborator
Emalex Biosciences Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related) An AE was any untoward medical condition that occurs in a participant while participating in this clinical study. It can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not related to the study. An SAE was any untoward medical occurrence that at any dose met one, more of the following criteria: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. The relationship of the study drug in causing or contributing to the AE whether unrelated, possibly related, or probably related was decided by investigator medical judgment. From start of study drug administration until 30 days after last dose (Up to Month 13)
Primary Change From Baseline in Hematology Parameters: Basophils to Leukocytes Ratio Reported in Percentage of Cells Basophils/Leukocytes was measured in percentages (%). Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in basophils to leukocytes ratio is reported in terms of percentage of cells. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells Eosinophils/Leukocytes was measured in percentages (%). Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in eosinophils to leukocytes ratio is reported in terms of percentage of cells. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Erythrocytes Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in hematology parameter erythrocytes was reported. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Hematocrit Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in hematology parameter hematocrit was reported. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Hemoglobin Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in hematology parameter hemoglobin was reported. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Leukocytes and Platelets Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in hematology parameters (Leukocytes and Platelets) expressed in 10^9 cells per liter were reported. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells Lymphocytes/leukocytes was measured in percentages (%). Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in lymphocytes to leukocytes ratio is reported in terms of percentage of cells. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Monocytes to Leukocytes Ratio Reported in Percentage of Cells Monocytes/leukocytes was measured in percentages (%). Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in monocytes to leukocytes ratio is reported in terms of percentage of cells. Baseline up to Month 12
Primary Change From Baseline in Hematology Parameters: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells Neutrophils/leukocytes was measured in percentages (%). Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in neutrophils to leukocytes ratio is reported in terms of percentage of cells. Baseline up to Month 12
Primary Change From Baseline in Serum Chemistry Parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Lactase Dehydrogenase Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in Serum chemistry parameters (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, and lactate dehydrogenase) were reported. Baseline up to Month 12
Primary Change From Baseline in Serum Chemistry Parameters: Albumin, Globulin and Protein Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in Serum chemistry parameters (albumin, globulin and protein) were reported. Baseline up to Month 12
Primary Change From Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Chloride, Cholesterol, Glucose, Phosphate, Potassium, Sodium, Triglyceride and Urea Nitrogen Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in Serum chemistry parameters (bicarbonate, calcium, chloride, cholesterol, glucose, phosphate, potassium, sodium, triglyceride, urea nitrogen) expressed in millimoles per liter (mmol/L) were reported. Baseline up to Month 12
Primary Change From Baseline in Serum Chemistry Parameters: Bilirubin, Creatinine and Direct Bilirubin Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in Serum chemistry parameters (bilirubin, creatinine and direct bilirubin) expressed in micromole per liter (mcmol/L) were reported. Baseline up to Month 12
Primary Change From Baseline in Hemoglobin A1c (HbA1c) HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average blood glucose concentration over prolonged periods of time. Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in HbA1c was reported. Baseline up to Month 12
Primary Change From Baseline in Vital Signs Parameter: Diastolic Blood Pressure and Systolic Blood Pressure Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in vital signs parameters diastolic blood pressure and systolic blood pressure and according to the assessment position (supine and standing) expressed in millimeter(s) of mercury (mmHg) was reported. Baseline up to Month 12
Primary Change From Baseline in Vital Signs Parameter: Pulse Rate Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in vital sign parameter pulse rate and according to assessment position (supine and standing) was reported. Baseline up to Month 12
Primary Change From Baseline in Vital Signs Parameter: Body Mass Index [BMI] Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in vital signs parameter BMI was reported. Baseline up to Month 12
Primary Change From Baseline in Vital Signs Parameter: Height Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in vital signs height was reported. Baseline up to Month 12
Primary Change From Baseline in Vital Signs Parameter: Weight Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change from baseline in vital signs parameter weight was reported. Baseline up to Month 12
Primary Change From Baseline in Electrocardiogram (ECG) Values Parameters: Aggregate PR Interval, Aggregate QRS Duration, Aggregate QT Interval, and Aggregate QTc Interval Baseline was defined as the last measurement taken before the first dose of open-label treatment on Day 1 of current study. Change From Baseline in ECG parameters aggregate PR interval, aggregate QRS duration, aggregate QT interval, and aggregate QTc interval expressed in millisecond (msec) was reported. Baseline to Month 12
Primary Number of Participants With Clinically Significant Abnormal Physical Examination Findings Physical examination included examination of the following body areas and systems: Head, Eyes, Ears, Nose, Mouth, Throat, Neck (including Thyroid), Thorax, Abdomen, Urogenital, Extremities, Neurological, Skin and Mucosae and Others. Any clinically significant abnormalities in physical examination were judged by the investigator. Only non-zero values are reported. Baseline up to Month 12
Secondary Change From Baseline in the Yale Global Tic Severity Scale -Total Tic Score (YGTSS-TTS) at Months 1, 3, 6, 9 and 12 The YGTSS was a clinician-completed rating scale used to quantify overall tic severity as well as specific subdomains of tic number, frequency, intensity, complexity and interference. Each of these subdomains was scored, on a 0 to 5 scale, separately for motor and vocal tics and then summed across both motor and vocal tics to yield a total tic score ranging from 0 to 50. Higher scores represent more severe symptoms. A negative change from baseline indicates improvement. Baseline up to Months 1, 3, 6, 9 and 12
Secondary Change From Baseline in the Yale Global Tic Severity Scale - Impairment (YGTSS-I) at Months 1, 3, 6, 9 and 12 The YGTSS was a clinician-completed rating scale used to quantify overall tic severity as well as specific subdomains of tic number, frequency, duration, intensity, and complexity. Each of these subdomains was scored, on 0 to 5 scale, separately for an overall impairment rating from (0 = ''none'' to 50 = ''severe''). Higher score represent more severe symptoms. A negative change from baseline indicates improvement. Baseline up to Months 1, 3, 6, 9 and 12
Secondary Change From Baseline in the Yale Global Tic Severity Scale - Global Score (YGTSS-GS) at Months 1, 3, 6, 9 and 12 The YGTSS was a clinician-completed rating scale used to quantify overall tic severity as well as specific subdomains of tic number, frequency, duration, intensity, and complexity. Each of these subdomains was scored, on a 0 to 5 scale, separately for motor and vocal tics and then summed across both motor and vocal tics to yield a tic severity score ranging from 0 to 50. The YGTSS also provides for an overall impairment rating (0 = ''none'' to 50 = ''severe''). YGTSS-GS is the total of YGTSS-TTS and YGTSS-I. The maximum YGTSS Global score is 100, while the maximum motor score is 25, the maximum vocal score is 25, and the maximum impairment score is 50. Higher scores indicate more severe tics. A negative change from baseline indicates improvement. Baseline up to Months 1, 3, 6, 9 and 12
Secondary Change From Baseline in Clinical Global Impression of Tourette Syndrome of Severity (CGI-TS-S) at Months 1, 3, 6, 9, 12 The CGI consists of 2 reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The CGI severity scale (CGI-TS-S) ranges from 1 = "not ill at all" to 7 = "among the most extremely ill." Higher scores represent more severe symptoms. A negative change from baseline indicates improvement. Baseline up to Months 1, 3, 6, 9, 12
Secondary Clinical Global Impression Tourette Syndrome of Improvement (CGI-TS-I) Scores at Months 1, 3, 6, 9 and 12 The CGI consists of 2 reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The scale ranges from 1 = "very much improved" to 7 = very much worse" for the CGI-TS-I. Higher score represent more severe symptoms. Months 1, 3, 6, 9 and 12
Secondary Change From Baseline in Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL) Total Score at Months 1, 3, 6, 9 and 12 The C&A-GTS-QOL was a 27-item questionnaire specific to TS patients that asks the patient to assess the extent to which their quality of life is impacted by their symptoms. The C&A-GTS-QOL consists of 6 subscales (cognitive [score range 0-32], coprophenomena [range 0-12], psychological [range 0-24], physical [range 0-12], obsessive-compulsive [range 0-16], and activities of daily living (ADL) [range 0-12] and uses a 5 point Likert scale ranging from no problem to extreme problem. Scores for six subscales were generated by summing items and, for ease of interpretation, transformation to a range of 0 to 100 (100* [(observed score-min possible score)/(max possible score-min possible score)]). Total score, resulted from sum of the subscale scores, was also normalized to a 0 to 100 range. Higher score indicated worst quality of life. A negative change from baseline indicates better quality of life. Baseline up to Months 1, 3, 6, 9 and 12
See also
  Status Clinical Trial Phase
Recruiting NCT05566236 - Board Game Project for Adolescents With Tourette Syndrome N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT05628805 - Theta Burst Stimulation to Improve Inhibitory Motor Physiology in Tourette Syndrome Early Phase 1
Recruiting NCT05558566 - Neurofeedback From the Supplementary Motor Area for Tourette Syndrome N/A
Completed NCT04578912 - Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics N/A
Not yet recruiting NCT05188274 - A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette Syndrome N/A
Completed NCT05184478 - Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? A Pilot Study Phase 1/Phase 2
Recruiting NCT05696769 - Tourette Discrimination (TD) Stigma Scale
Completed NCT04449003 - Influence of Stress and Psychiatric Symptoms on Children With Tourette Syndrome
Recruiting NCT04087616 - Internet-based CBIT for Children With Chronic Tics N/A
Completed NCT03765463 - Extinction Learning in Youth With Tourette Syndrome N/A
Completed NCT05434546 - A Study to Explore the Effect of Sepranolone in Tourette Syndrome Phase 2
Not yet recruiting NCT04179435 - Cognitive and Brain Development in Adolescents With Gilles de la Tourette Syndrome N/A
Recruiting NCT06385535 - Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder N/A